Table 1.

Case	Prior treatments	Age	Subtype	cStage	pStage	Grade	Method of isolation	Total number of TIL (IL-2) 106	Total number of TIL (IL-2 + 4-1BB) 106	TIL/fragment (IL-2) 106	TIL/fragment (IL-2 + 4-1BB) 106	Number of fragment (IL-2)	Number of fragment (IL-2 + 4-1BB)
1	Panitsumab, Abraxane, Carboplatin, FAC	52	IBC-TNBC	cT4dN3bM0 IIIc	ypT4bN3b	2	Enzymatic digestion	* NA	NA	** NG	NG	NA	NA
2	PTX, FAC	63	IBC-TNBC	cT4dNxM1 IV	ypT1miN2a	3	Enzymatic digestion Mechanical disruption	NA	NA	NG	NG	NA	NA
3	Capecitabine	76	IBC-TNBC	cT4dN2M0 IIIB	ypT4dN3	2	Fragment	NA	NA	NG	NG	NA	NA
4	none	71	TNBC	cT1cN0M0 IA	ypT1aN0	2	Fragment	20.8	34.3	3.5	11.4	6	3
5	Abraxane, FAC	55	TNBC	cT2N0M0 IIA	ypT1aN0	3	Fragment	16.6	34.6	4.2	17.3	4	2
6	PTX, FAC	57	IBC-TNBC	cT4dN2M0 IIIB	ypT0N0	3	Fragment	16.9	520.3	1.2	37.2	14	14
7	PTX, FAC	34	TNBC	cT2N1M0 IIB	ypT1cN1	3	Fragment	30.8	519.3	3.8	64.9	8	8
8	PTX, FAC	51	TNBC	cT2N0M0 IIA	ypT1cN0	3	Fragment	111.1	160.1	9.3	13.3	12	12
9	PTX, FAC	79	TNBC	cT3N1M0 IIIA	ypT2N0	3	Fragment	0.00629	5.8	0.000524	0.481	12	12

^*NA = None Available

^**NG = No Growth